Results 81 to 90 of about 10,191,062 (296)

Prevalence of Hepatitis C virus Genotype 3a in patients with Hodgkin and Non-Hodgkin Lymphoma

Iranian Journal of Microbiology, 2017
Background and Objectives: Hepatitis C virus (HCV) is a major public health problem worldwide. Replication and persistence of HCV genome have been described in the liver tissue as well as B cells lymphocyte. Several investigations have reported that long-
Hashem Radmehr, Manoochehr Makvandi, Alireza Samarbafzadeh, Ali Teimoori, Niloofar Neisi, Mojtaba Rasti, Sara Abasifar, Hasan Soltani, Samaneh Abbasi, Hadis Kiani, Hamide Mehravaran, Azarakhsh Azaran, Toran Shahani   +12 more
doaj  

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG

EJNMMI Research, 2020
Background In order to study the CXCR4 expression with [68Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [68Ga]pentixafor PET/CT imaging in a spectrum of lymphomas and to compare it with ...
Qingqing Pan, Yaping Luo, Yan Zhang, Long Chang, Ji Li, Xinxin Cao, Jian Li, Fang Li   +7 more
doaj   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source

Non-Hodgkin’s Lymphomas [PDF]

Journal of the National Comprehensive Cancer Network, 2010
Andrew D, Zelenetz, Jeremy S, Abramson, Ranjana H, Advani, C Babis, Andreadis, Nancy, Bartlett, Naresh, Bellam, John C, Byrd, Myron S, Czuczman, Luis E, Fayad, Martha J, Glenn, Jon P, Gockerman, Leo I, Gordon, Nancy Lee, Harris, Richard T, Hoppe, Steven M, Horwitz, Christopher R, Kelsey, Youn H, Kim, Ann S, LaCasce, Auayporn, Nademanee, Pierluigi, Porcu, Oliver, Press, Barbara, Pro, Nashitha, Reddy, Lubomir, Sokol, Lode J, Swinnen, Christina, Tsien, Julie M, Vose, William G, Wierda, Joachim, Yahalom, Nadeem, Zafar   +29 more
openaire   +3 more sources

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

PROFILES registry: Quality of life non-Hodgkin lymphoma May 2010

, 2016
The PROFILES registry offers scientific data in the area of medical psychology and more specific on quality of life of cancer survivors. The PROFILES registry is open to academics anywhere in the world for scientific purposes, free of charge. The archive
Oerlemans, S. (Tilburg University), Poll - Franse, Prof. Dr. L. van de (Tilburg University) DAI=info:eu-repo/dai/nl/327781785   +1 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Diffuse large B-cell lymphoma in the uterus with unexpected manifestations: a case report

Journal of Medical Case Reports
Background Lymphoid neoplasm is a common disease, arising from lymphoid cells. It is divided into Hodgkin lymphoma and non-Hodgkin lymphoma. Non-Hodgkin lymphoma can be intranodular or extranodular, which happens in 25% of primary cases.
Kenana Tawashi, Tuka Hamasho, Mustafa Al-Hussien, Ameen Ammar   +3 more
doaj   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source